From Epigenetic to Proteomic to Organ-Specific: Which Aging Biomarkers Are Closest to Clinical Use?
The biomarker field in longevity now has a familiar problem: it is producing more interesting measurements than medicine yet knows […]
Analysis
What the DO-HEALTH Omega-3 Trial Actually Showed About Slowing Biological Aging
The DO-HEALTH omega-3 paper became one of those longevity studies that was easy to summarize too quickly. A daily gram
The Senolytics Pipeline in 2026: Where the Science Still Looks Strong — and Where It Doesn’t
Few ideas in longevity science remain as intuitively powerful as senolytics. If aging tissues accumulate senescent cells — damaged cells
Why Chronic Inflammation Keeps Moving to the Center of Longevity Science
For years, chronic inflammation sat in longevity science as both a familiar fact and a slightly unsatisfying explanation. Everyone knew
Why Longitudinal Data May Be the Real Moat in Longevity
Longevity companies often talk as if their advantage lies in a proprietary clock, a sharper scan, a larger omics panel,
Longevity Capital in 2026: The Four Buckets Still Getting Funded
There is a temptation to talk about longevity investing as if it were a single sector. It is not. The
Are GLP-1s the First Longevity Drugs — or Just the First Big Proxy?
Few drug classes have moved from endocrinology into so many neighboring territories so quickly. What began as a diabetes story